What Alpertan D Treats: Main Uses and Benefits

The combination medication Alpertan D is applied in addressing symptoms related to systemic imbalance, playing a role in the management of persistently high blood pressure. This treatment is commonly used to help with conditions such as essential hypertension and when a patient's pressure is not adequately managed by a single medication.

The therapeutic focus is on reducing elevated pressure readings and addressing symptoms that create noticeable functional strain on the cardiovascular system. It is relevant for easing symptoms in patients with co-existing conditions like Type 2 diabetes, and assists with maintaining functional stability.

“Controlling blood pressure effectively plays a role in managing conditions associated with heightened physiological activity.”

This treatment is considered relevant for the long-term management of chronic hypertension, where it contributes to easing the overall symptom load associated with vascular strain.

Quick Fact: Relief for Elevated Pressure Readings

Regulatory References

1. NIH DailyMed Label for Valsartan/HCTZ

Who Can and Cannot Use Alpertan D?

Alpertan D is approved for use in adults with hypertension. However, official regulatory documents strictly define several populations for whom use is contraindicated or not recommended.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for patients with known hypersensitivity to Valsartan, Hydrochlorothiazide, or any sulfonamide-derived drug. Use is also prohibited in patients with anuria (inability to produce urine) or severe impairment of renal function (creatinine clearance < 30 mL/min) and severe hepatic impairment or cholestasis. The drug is contraindicated during the second and third trimesters of pregnancy. Furthermore, patients with diabetes must not use this medicine if they are concurrently taking aliskiren.

Restricted and Limited Use

Use is not recommended in children and adolescents under 18 years of age due to lack of established data. For patients who are breastfeeding, the medicine is also not recommended. Use is restricted in patients who are severely volume- or salt-depleted, where correction must occur prior to initiation. Patients with Systemic Lupus Erythematosus (SLE) or certain refractory electrolyte imbalances are also subject to specific regulatory limitations.

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the co-administration of Alpertan D (Valsartan/Hydrochlorothiazide) with certain medicinal products and substances. This section is strictly based on formally documented interaction patterns.

Contraindicated and Restricted Combinations

Co-administration with Aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR less than 60 mL/min/1.73 m^2). This restriction is due to the documented risk of severe renal impairment, hypotension, and hyperkalemia resulting from dual inhibition of the Renin-Angiotensin System (RAS).

Concomitant use with potassium-sparing diuretics or potassium supplements is generally not recommended due to the increased risk of significant hyperkalemia.

Pharmacodynamic and Exposure Effects

Interactions with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may reduce the antihypertensive effect and can deteriorate renal function. Co-administration with Lithium is documented to reduce Lithium's renal clearance, significantly increasing the risk of lithium toxicity.

Substances that affect absorption, such as the ion exchange resins Cholestyramine or Colestipol, reduce the exposure to the Hydrochlorothiazide component. To mitigate this effect, a mandatory separation time rule applies: Alpertan D must be taken at least four hours before or four to six hours after these resins. Potentiation of orthostatic hypotension is officially noted when Alpertan D is taken with alcohol, barbiturates, or narcotics.

Regulation of Vascular Tone (Resistance)

This core mechanism involves the drug acting as an Angiotensin II Receptor Antagonist (ARB) by specifically blocking the AT1 receptors on vascular smooth muscle cells. Preventing Angiotensin II from binding interrupts the signaling cascade for blood vessel constriction, which results in the relaxation and widening of peripheral arteries. This action on the vascular system reduces the resistance to blood flow.

Modulation of Circulating Fluid Volume

The second pathway addresses fluid balance by modulating the epithelial sodium channel (ENaC) in the kidney's collecting ducts. This action reduces the reabsorption of sodium and, consequently, water back into the body. This targeted influence on renal transport results in a diuretic effect, which decreases the total circulating fluid volume.

Integrated Systemic Modulation

Alpertan D operates by engaging both the vascular and renal mechanistic domains simultaneously. The combined reduction in both vascular resistance (from receptor blockade) and circulatory fluid volume (from renal modulation) leads to an integrated modulation of systemic pressure dynamics.

How to Use Alpertan D: Official Administration Guidelines

Alpertan D is an oral fixed-dose combination (FDC) therapy used in the management of high blood pressure. The administration pattern is structured by guidelines to ensure consistent usage and proper dosing over time.

Administration Method and Frequency

The medicine is supplied as an oral tablet and must be swallowed whole with water. The official dosing schedule specifies administration once daily. The tablets may be taken with or without food; however, it is generally recommended to take the dose in the morning.

Official Dosing and Adjustment Rules

The typical adult starting and maintenance regimen is often 160 mg valsartan / 12.5 mg hydrochlorothiazide once daily, though various strengths are available. The maximum recommended daily dose is constrained to 320 mg valsartan / 25 mg hydrochlorothiazide.

Dosage adjustments (titration) are typically implemented only after 2 to 4 weeks of therapy, reflecting the time required for the blood pressure lowering effect to fully manifest. If a dose is missed, it should be taken as soon as remembered, unless the next dose is due shortly, in which case the missed dose is skipped to maintain the once-daily schedule.

Population and Procedural Constraints

Official use is subject to specific criteria concerning patient physiology. The product is not recommended for use in pediatric patients (under 18 years of age) and is also not recommended for patients with severe renal impairment (creatinine clearance le 30 mL/min). In patients with mild to moderate hepatic impairment, the valsartan dose component should not exceed 80 mg. Additionally, therapy should be initiated only after correction of any pre-existing volume or sodium depletion.

Research Evidence / Overview of Studies for Alpertan D

Evidence for Use in Essential Hypertension

Research examined the clinical evaluation of Alpertan D (the combination of Valsartan and Hydrochlorothiazide) in short-term Randomized Controlled Trials (RCTs). These studies were designed to evaluate the combination's influence on high blood pressure, a condition characterized by outcomes related to physiological strain or stress. Researchers carefully monitored the adult study populations over typical time intervals of 8 to 16 weeks. The primary outcomes researchers focused on included measuring the change in blood pressure numbers, specifically for Systolic and Diastolic readings.

Research describes that when the two components were used together, patterns related to blood pressure changes were observed. Trials documented measured differences in both pressure readings compared to when either component was used alone, or when compared to a placebo. The research also described that a higher percentage of the observed populations reached the pre-defined target blood pressure goals during the combination study period.

Evidence When Blood Pressure is Not Controlled by Single Medicines

Research has also explored scenarios where high blood pressure is not adequately managed by a single medicine (monotherapy). Comparative RCTs were conducted for this specific population of adults whose pressure remained elevated despite consistent use of a monotherapy. Studies monitored outcomes related to systemic or functional imbalance over shorter follow-up durations, typically 4 to 12 weeks, after the dual combination was initiated.

Research reported that further measured differences in both systolic and diastolic pressure measurements were noted following the change to the combination therapy. Research explored whether a specific percentage of previously uncontrolled patients reached a target BP goal following the initiation of the dual therapy, and documented those percentages.

Evidence Gaps and Areas of Uncertainty

While there is substantial evidence derived from short-term RCTs regarding blood pressure changes, the primary data is based on a surrogate endpoint (blood pressure numbers) rather than direct data on major long-term clinical events. This distinction means that evidence contributes to understanding symptom patterns, but research does not provide individual predictions. Furthermore, comparative evidence that directly contrasts the long-term outcomes of this specific fixed-dose combination against other commonly used dual antihypertensive therapies is limited. Subgroup findings are uncertain for certain other groups not heavily represented in the initial trials, and data for certain groups remain insufficient.

Common questions about Alpertan D (FAQ)

Q: What is Alpertan D used for?

A: Alpertan D is a prescription medication used to treat high blood pressure (hypertension). By helping to lower blood pressure, it helps reduce the risk of serious heart problems, such as heart attacks and strokes.

Q: How should I take Alpertan D?

A: Take Alpertan D exactly as your healthcare provider tells you. It is usually taken once a day, with or without food. It is important to continue taking this medication even if you feel well. Do not stop taking it without first talking to your doctor.

Q: What are the possible side effects of Alpertan D?

A: Common side effects can include dizziness, lightheadedness, and headache. Serious side effects are rare but may occur. You should contact your doctor if you experience any symptoms that are concerning, persistent, or worsen over time.

Q: What should I avoid while taking Alpertan D?

A: Avoid driving or operating heavy machinery until you know how Alpertan D affects you, as it may cause dizziness or lightheadedness, especially when you first start taking it. You should also discuss all other medications and supplements you take with your healthcare provider to check for potential drug interactions.

Official Storage and Disposal Requirements

Storage and disposal instructions for Alpertan D (Valsartan/Hydrochlorothiazide) are defined by regulatory labeling to ensure product quality and safety.

Mandatory Storage Conditions

Official Disposal Procedures

Expired or unused tablets should be disposed of securely. The preferred method is to take the product to an authorized drug take-back program. If a take-back option is unavailable, the tablets may be prepared for household trash by mixing them with an undesirable substance (such as used coffee grounds) and sealing the mixture in a bag before discarding.